FDA
-
-
-
-
-
-
-
Lipocine's postpartum depression drug fails primary endpoint in phase 3 trial
-
-
-
-
-
-
-
2026 Asset Growth: Why Federal Compliance Is the New Metric
-
-
-
-
-
-
-
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Lipocine Inc (LPCN)
-
-
-
-
-
-
-
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology
-
-
-
-
-
-
-
Lipocine Announces FDA Labeling Changes for Testosterone Products
-
-
-
-
-
-
-
Lipocine (LPCN) Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO in South Korea
-
322,899 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

